These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23072771)

  • 1. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis.
    Cortesi PA; Scalone L; D'Angiolella L; Belisari A; Fusco F; Olivieri I; Mantovani LG
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S126-31. PubMed ID: 23072771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriatic arthritis: pharmacoeconomic considerations.
    Olivieri I; Mantovani LG; D'Angelo S; Padula A; de Portu S
    Curr Rheumatol Rep; 2009 Aug; 11(4):263-9. PubMed ID: 19691929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden of psoriatic arthritis.
    Ackermann C; Kavanaugh A
    Pharmacoeconomics; 2008; 26(2):121-9. PubMed ID: 18198932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic issues in psoriatic arthritis.
    Olivieri I; D'Angelo S; Palazzi C; Padula A; Lubrano E; Mantovani LG
    J Rheumatol Suppl; 2012 Jul; 89():103-5. PubMed ID: 22751607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review.
    D'Angiolella LS; Cortesi PA; Lafranconi A; Micale M; Mangano S; Cesana G; Mantovani LG
    Pharmacoeconomics; 2018 May; 36(5):567-589. PubMed ID: 29441473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
    Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
    Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.
    O'Connor J; Rice S; Smith A; Rodgers M; Lopez RR; Craig D; Woolacott N
    Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional review of patients with psoriatic arthritis in secondary care in the West Midlands: prevalence, disease activity and eligibility for anti-tumour necrosis factor therapy.
    Bateman J; Cardy CM; Khan SY; Menon A; Obrenovic K; Rowe IF; Erb N
    Clin Exp Rheumatol; 2009; 27(6):935-9. PubMed ID: 20149308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
    Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
    J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
    Eder L; Thavaneswaran A; Chandran V; Gladman DD
    Ann Rheum Dis; 2014 Jun; 73(6):1007-11. PubMed ID: 23619157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence.
    Sideris E; Corbett M; Palmer S; Woolacott N; Bojke L
    Pharmacoeconomics; 2016 Nov; 34(11):1101-1110. PubMed ID: 27272887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
    Olivieri I; Cortesi PA; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Ciampichini R; Cutro MS; Mathieu A; Matucci-Cerinic M; Punzi L; Scarpa R; Mantovani LG;
    Clin Exp Rheumatol; 2016; 34(1):68-75. PubMed ID: 26633622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept in psoriatic arthritis.
    Spadaro A; Lubrano E; Ferrara N; Scarpa R
    J Rheumatol Suppl; 2012 Jul; 89():74-6. PubMed ID: 22751599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
    Cummins E; Asseburg C; Punekar YS; Shore E; Morris J; Briggs A; Fenwick E
    Value Health; 2011 Jan; 14(1):15-23. PubMed ID: 21211482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.
    Saad AA; Hyrich KL; Ashcroft DM
    Expert Opin Drug Saf; 2011 Mar; 10(2):219-26. PubMed ID: 21208138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
    Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
    Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.